Summary of Significant Accounting Policies (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2025

Dec. 31, 2024

Schedule of percentages of revenue recognized from license agreement partners

	For the Three Months				As of		As of
	Ended March 31,				March 31,		December 31,
	2025		2024		2025		2024
	% of operating expenses				% of accounts payable
Vendor A	34	%	50	%	49	%	43	%
Vendor B	1	%	3	%	2	%	2	%
Vendor C	9	%	5	%	4	%	8	%
Vendor D	2	%	—		11	%	—
	46	%	58	%	66	%	53	%

	For the Year Ended
	December 31,				As of December 31,
	2024		2023		2024		2023
	% of operating expenses				% of accounts payable
Vendor A	62	%	33	%	43	%	40	%
Vendor B	1	%	14	%	2	%	—
Vendor C	3	%	8	%	8	%	10	%
Vendor D	—		—		—		19	%
	66	%	55	%	53	%	69	%

Cara Therapeutics, Inc.

Schedule of percentages of revenue recognized from license agreement partners

The percentages of revenue recognized from license agreement partners of the Company in the years ended December 31, 2024, 2023 and 2022 are included in the following table:

	Revenue
	Year Ended December 31,
	2024		2023		2022
License Agreement Partner:
CSL Vifor*	59	%	92	%	100	%
Maruishi	41	%	8	%	—	%

* Includes amounts earned from Vifor Fresenius Medical Care Renal Pharma Ltd. and Vifor International prior to Vifor International’s assignment of its rights and obligations to Vifor Fresenius Medical Care Renal Pharma Ltd. in May 2022.